Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D

Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D is a pharmaceutical importer and buyer based in Zambia, specializing in the procurement of finished pharmaceutical formulations. The company operates as a key player in Zambia's pharmaceutical distribution network, focusing on the importation of essential medicines to meet the country's healthcare needs. While specific details about its headquarters, parent company, and exact role in the distribution chain are not publicly available, the company's activities suggest a significant presence in the Zambian pharmaceutical sector.

The distribution network of Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D is not publicly detailed. However, given its substantial import volume of $1.3 million USD from India over 25 shipments, it is likely that the company has established a robust logistics framework. This would include warehousing facilities and transportation capabilities to ensure the efficient distribution of pharmaceutical products across Zambia. The company's geographic coverage likely spans the entire country, facilitating the supply of essential medicines to both urban and rural areas.

Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D plays a pivotal role in Zambia's pharmaceutical supply chain as a primary importer of finished pharmaceutical formulations. By sourcing a diverse range of medicines from India, the company contributes significantly to the availability of essential drugs in the Zambian market. Its activities support the healthcare system by ensuring a steady supply of quality-assured medicines, thereby enhancing the country's capacity to address public health challenges.

The company's sourcing strategy exhibits a high degree of concentration, with all 25 shipments originating from a single supplier, MISSIONPHARMA LOGISTICS INDIA PRIVATE LIMITED. This single-source dependency could pose risks related to supply chain disruptions, such as delays or quality issues. However, the consistent relationship over multiple shipments suggests a stable and reliable partnership. To mitigate potential risks, it would be prudent for Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing dependency on a single source.

The resilience of Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D's supply chain is closely tied to its exclusive relationship with MISSIONPHARMA LOGISTICS INDIA PRIVATE LIMITED. While this partnership has demonstrated reliability, the lack of alternative suppliers may expose the company to risks such as supply interruptions or regulatory changes affecting the sole supplier. The company's importation of 142 unique formulations indicates a diverse product portfolio, which can help mitigate some risks associated with product-specific supply issues. Nonetheless, establishing relationships with additional suppliers could further strengthen the company's supply chain resilience.

The concentrated sourcing pattern of Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D positions it as a significant partner for MISSIONPHARMA LOGISTICS INDIA PRIVATE LIMITED, potentially leading to favorable terms and prioritization. For Indian exporters, this presents an opportunity to engage with a major importer in Zambia. However, the exclusivity of the current supplier relationship may limit immediate opportunities for new entrants. To capitalize on this market, Indian exporters should consider offering competitive pricing, ensuring high-quality standards, and demonstrating the ability to meet the specific needs of the Zambian market to attract Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D as a new supplier.

The Zambia Medicines Regulatory Authority (ZAMRA) is the statutory body responsible for regulating and controlling the manufacture, importation, storage, distribution, supply, sale, and use of medicines and allied substances in Zambia. Established under the Medicines and Allied Substances Act No. 3 of 2013, ZAMRA's primary objective is to ensure that all medicines and allied substances available to the Zambian public consistently meet the set standards of quality, safety, and efficacy. The authority oversees various regulatory activities, including marketing authorization, facility inspections, advertising and promotion, and post-marketing surveillance. (zamra.co.zm)

Importers of medicinal products into Zambia are required to obtain an import permit from ZAMRA. The application process involves paying a pre-clearance fee for quality assurance purposes. While holding a pharmaceutical license is not mandatory for importers, they must apply for a permit and pay the prescribed fee. ZAMRA has the authority to inspect premises where medicines are stored to ensure compliance with regulatory requirements. In cases of non-compliance, the authority can reject or revoke permits, and may require the disposal of non-compliant products at the importer's expense. (swm-programme.info)

Medicinal products imported into Zambia must undergo quality assurance processes, including batch testing and stability assessments, to ensure they meet the required standards of safety, quality, and efficacy. Labeling requirements stipulate that product information must be accurate and relevant, with specific language requirements to ensure clarity for consumers. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the market. Compliance with these standards is essential for maintaining public health and safety. (zamra.co.zm)

Between 2024 and 2026, Zambia has implemented several regulatory changes affecting pharmaceutical imports. Notably, in February 2026, ZAMRA engaged the pharmaceutical industry to address concerns about the increasing importation of unregistered medicines and allied substances. The authority emphasized its mandate to ensure that only safe, effective, and quality-assured medicines reach the public. These developments underscore the importance of compliance with regulatory standards for all pharmaceutical importers.

Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D's focus on importing advanced antibiotics and corticosteroids aligns with the therapeutic needs of the Zambian population. The substantial import value of metronidazole and hydrocortisone indicates a strategic emphasis on these critical areas. The market demand for these products is driven by the prevalence of infections and inflammatory conditions in Zambia, necessitating a reliable supply of effective treatments. By concentrating on these therapeutic categories, the company plays a crucial role in addressing significant public health challenges.

Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. The company's preference for a single supplier, MISSIONPHARMA LOGISTICS INDIA PRIVATE LIMITED, suggests a streamlined procurement process and potentially favorable terms. This approach allows the company to maintain a consistent supply of quality-assured products, ensuring the availability of essential medicines in the Zambian market.

Based on its product mix, Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D serves a broad segment of the Zambian market, including retail pharmacies, hospitals, and government tenders. The importation of essential medicines positions the company as a key supplier to various healthcare institutions, contributing to the overall healthcare infrastructure. By ensuring the availability of critical drugs, the company supports the delivery of quality healthcare services across the country.

There is a realistic opportunity for new Indian suppliers to enter the Zambian market by partnering with Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D. The company's substantial import volume and focus on essential medicines indicate a steady demand for quality pharmaceutical products. To capitalize on this opportunity, Indian exporters should offer competitive pricing, ensure compliance with ZAMRA's regulatory standards, and demonstrate the ability to meet the specific needs of the Zambian market. Diversifying the supplier base could also enhance supply chain resilience and reduce dependency on a single source.

Indian exporters seeking to supply Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D and the Zambian market must adhere to ZAMRA's regulatory requirements. This includes obtaining the necessary import permits, ensuring compliance with Good Manufacturing Practices (GMP), and meeting quality assurance standards. Products must undergo batch testing and stability assessments, and labeling must meet specific language and content requirements. Additionally, exporters should be prepared to provide documentation demonstrating compliance with ZAMRA's regulations to facilitate the importation process.

To establish a relationship with Xxssixxphaxxa AXX Vxxsinxxrodxxj 9xx354xxlynxx D, Indian exporters should initiate contact to understand the company's specific product requirements and quality standards.